logo
'I was 35 and didn't even know what MS was'

'I was 35 and didn't even know what MS was'

Yahoo10-03-2025

A woman who was told she had multiple sclerosis (MS) at 35 says she had never heard of the disease, even though it is most commonly diagnosed in young adults.
Kate Dawson, from Ponteland, Northumberland, is now 49 and wants more people to be aware of the symptoms so they can get help earlier.
The condition affects the brain and spinal code and can cause pain, mobility issues and fatigue.
More than 150,000 people live with it in the UK, yet a new survey from the MS Society shows only one in five UK adults know it is most likely to be diagnosed in people in their 30s and 40s.
The charity spoke to 2,000 people and also found only a third knew women were more likely to be diagnosed with MS than men, and that smoking and obesity increased a person's risk of developing it.
Ms Dawson, a fitness instructor at the time, said she became aware something was wrong when running became more difficult.
"I kept tripping over tree roots, my right leg would start dragging and I had to be aware of lifting it," she said
She later discovered an earlier medical episode may have been an early symptom.
"During my GSCEs, I lost the sight in one eye for a bit and I just thought it was stress, but they told my dad they couldn't diagnose it at that stage because you had to have multiple episodes.
"It was horrible when I finally found out, I was in denial, I didn't want to tell people, I didn't even tell my mum, I didn't want to burden anyone else."
Ms Dawson said her main symptoms now were fatigue, loss of balance and strength in her legs.
"But I do a lot of cold water swimming and that seems to really help," Ms Dawson added.
MS is the most common neurological condition among young adults and Sarah Rawlings from the MS said it could be "debilitating, exhausting and unpredictable".
She added: "However greater understanding can make a huge difference and make conversations with family, friends and employers that little bit easier."
Follow BBC North East on X, Facebook, Nextdoor and Instagram.
Scientists crack mystery of how MS gene spread
'My son's had more than 200 carers in five years'
Hopes for multiple sclerosis drugs trial
MS Society

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Demyelinating Diseases Therapeutics Market to Reach USD 45 Billion by 2034, Growing at 6.3% CAGR
Demyelinating Diseases Therapeutics Market to Reach USD 45 Billion by 2034, Growing at 6.3% CAGR

Yahoo

time14 hours ago

  • Yahoo

Demyelinating Diseases Therapeutics Market to Reach USD 45 Billion by 2034, Growing at 6.3% CAGR

Demyelinating Diseases Therapeutics Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- The global market for demyelinating diseases therapeutics is witnessing notable growth and transformation, fueled by the increasing prevalence of neurological disorders and the introduction of innovative treatment solutions. Valued at approximately USD 25 billion in 2024, the market is projected to reach an estimated USD 45 billion by 2034, progressing at a steady Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period from 2025 to 2034. Download PDF Brochure: A major contributor to this expansion is the rising incidence of multiple sclerosis (MS), along with other related disorders such as neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and chronic inflammatory demyelinating polyneuropathy (CIDP). The market is undergoing significant advancements through personalized medicine, biologics, and digital health integrations, shaping the way therapies are developed and delivered. Market Segmentation: A Detailed Breakdown The demyelinating diseases therapeutics market is categorized across several parameters including product type, therapeutic application, disease type, route of administration, distribution channels, therapeutic class, and patient demographics. Among product types, monoclonal antibodies, corticosteroids, and immunomodulators dominate due to their high efficacy and role in managing autoimmune responses central to these diseases. Multiple Sclerosis (MS) remains the largest disease segment due to its global prevalence, impacting nearly 2.8 million individuals worldwide. This segment benefits from a strong drug pipeline and sustained investment in research and development. In contrast, diseases like NMO and CIDP, though less prevalent, are becoming more prominent due to improved diagnostic capabilities and novel drug approvals. When it comes to therapeutic applications, Disease-Modifying Therapies (DMTs) are pivotal. These therapies reduce relapse rates and slow disease progression, particularly in MS, capturing the lion's share of the market. Symptomatic treatments, though secondary in market size, are essential for improving patients' quality of life and remain indispensable in overall disease management strategies. Route of Administration and Distribution Channels The preferred routes of administration in this market include injectable, oral, and infusion-based methods. Injectables lead due to their rapid efficacy and widespread use in administering monoclonal antibodies. However, oral therapies are quickly gaining popularity for their convenience and higher patient adherence, which could shift the administration landscape in coming years. From a distribution perspective, hospital pharmacies remain the dominant channel, especially for therapies requiring medical supervision or administration. Meanwhile, online pharmacies are emerging as strong contenders due to their convenience and role in chronic disease management. This growth is driven by increased internet penetration, telehealth services, and changing consumer behavior. Therapeutic Class and Demographic Insights In terms of therapeutic classification, biologics are leading the charge. These include monoclonal antibodies and recombinant proteins that target specific immune pathways. Biologics offer superior efficacy and fewer side effects, making them the preferred option in many treatment regimens. However, small molecules continue to hold value due to their affordability, oral availability, and ease of production, especially in cost-sensitive markets. Demographically, adult patients comprise the majority due to the typical onset age of MS and related disorders. However, pediatric treatments are on the rise as early diagnosis improves. The geriatric population is another growing segment, supported by the aging global population and increasing incidence of neurological conditions in older adults. These patients often require specialized care due to comorbidities and age-related drug interactions. Browse full Report - Market SegmentationType of Demyelinating Disease - Multiple Sclerosis (MS) - Neuromyelitis Optica (NMO) - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Acute Disseminated Encephalomyelitis (ADEM) Therapeutic Application - Disease-Modifying Therapies (DMTs) - Symptomatic Treatments - Corticosteroids - Monoclonal Antibodies - Other Immunotherapies & Supportive Care Route of Administration - Oral - Injectable (Subcutaneous, Intravenous) - Infusion Distribution Channel - Hospital Pharmacy - Retail Pharmacy - Online Pharmacy Therapeutic Class - Biologics - Small Molecules - Non-Biologics Patient Demographics - Adults - Pediatric - Geriatric Regional Insights and Global Landscape North America currently commands the largest market share, accounting for around 45% of global revenue in 2024. This dominance is underpinned by advanced healthcare systems, widespread access to therapies, and high levels of R&D investment. The U.S., in particular, plays a significant role with supportive regulatory policies and well-established pharmaceutical players. Europe follows closely, contributing approximately 30% to the market. Growth in this region is propelled by increasing awareness, government-supported healthcare systems, and a favorable environment for clinical research. Countries like Germany, France, and the UK are key hubs for drug development and patient care. The Asia-Pacific region is the fastest-growing market with a projected CAGR of 8% through 2034. Factors such as economic development, expanding healthcare infrastructure, and rising disease prevalence contribute to this rapid growth. Nations like China, India, and Japan are investing heavily in healthcare, which supports both access and innovation in therapeutic offerings. Latin America and the Middle East & Africa are also emerging as regions with untapped market potential. While they currently hold smaller shares, their projected CAGRs of 7% and 6% respectively reflect strong future growth, particularly in urban centers with improving access to care. Key Market Drivers The momentum in this market is largely attributed to scientific and technological advancements, including the development of next-generation therapies like monoclonal antibodies and targeted biologics. The rise of personalized medicine, where treatments are tailored based on patient-specific genetic and biomarker profiles, is reshaping therapeutic strategies. Regulatory developments are also influential. Accelerated approval pathways, especially for orphan and breakthrough therapies, have reduced time-to-market for promising treatments. In tandem, increased global healthcare spending, particularly in neurological and autoimmune sectors, is bolstering the adoption of advanced therapies. Challenges and Restraints Despite promising growth, the market faces a number of hurdles. One major challenge is the high cost of therapies, especially biologics, which limits access for patients in low- and middle-income regions. Prolonged regulatory approval timelines and complex compliance requirements can also delay product launches and increase costs for manufacturers. Supply chain disruptions, particularly in biopharmaceutical manufacturing, further complicate delivery and availability. The sector is also vulnerable to clinical trial failures, which can derail product pipelines and investor confidence. Additionally, generic and biosimilar competition can undercut revenues once patents expire, necessitating continuous innovation. Buy Now : Opportunities and Emerging Trends The market is rich with opportunities for expansion and innovation. Digital health technologies, such as telemedicine platforms and remote monitoring tools, are increasingly integrated into care pathways, enhancing both outcomes and convenience. These technologies also support real-time data collection and predictive analytics, aiding personalized care. Additionally, emerging markets offer considerable potential for growth. As awareness rises and infrastructure improves, pharmaceutical companies are investing in these regions to tap into large, underserved patient populations. The trend toward strategic partnerships, mergers, and acquisitions is another significant development. Collaborations between pharmaceutical firms and tech companies, particularly in AI-driven drug discovery and patient management, are redefining the way therapies are developed and delivered. Key Competitors Biogen Inc. Novartis International AG Roche Holding AG Sanofi S.A. Celgene Corporation (a Bristol-Myers Squibb Company) Merck KGaA Teva Pharmaceutical Industries Ltd. Genzyme Corporation (a Sanofi Company) EMD Serono, Inc. AbbVie Inc. GSK (GlaxoSmithKline) Vertex Pharmaceuticals Incorporated Pfizer Inc. Janssen Pharmaceuticals (a Johnson & Johnson Company) Horizon Therapeutics plc Recent Strategic Developments Company Name: Biogen Inc. Month & Year: August 2023 Type of Development: Product Launch Detailed Analysis: Biogen launched its latest multiple sclerosis (MS) therapy, an oral medication named Alectinib, in August 2023. This drug represents a significant advancement in the treatment landscape for MS, targeting a previously underserved patient demographic. The launch is crucial as the MS market increasingly shifts toward oral therapies that offer improved safety and convenience over traditional injections. Biogen's investment in clinical studies demonstrates their commitment to addressing unmet clinical needs. The release not only strengthens Biogen's portfolio but also rekindles competitive dynamics in the MS therapeutics market. Other companies may need to accelerate their research and focus on innovative delivery mechanisms to retain market share, indicating a potential uptick in R&D spending across the industry. Company Name: Novartis International AG Month & Year: July 2023 Type of Development: Regulatory Approval Detailed Analysis: In July 2023, Novartis received expedited approval from the FDA for its drug ofatumumab aimed at treating neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, debilitating condition, and this regulatory advancement opens new pathways for patients who have historically faced limited treatment options. This approval underlines a broader trend in the industry towards personalized medicine and targeted therapies. The positive regulatory news also strengthens Novartis's position in the demyelinating diseases market, compelling competitors to prioritize novel therapeutic approaches. As regulatory environments evolve, this approval may set a precedent that encourages pharmaceutical companies to innovate and invest heavily in rare disease therapies. Company Name: AbbVie Inc. Month & Year: September 2023 Type of Development: Merger Detailed Analysis: AbbVie entered a strategic merger with a biotech firm specializing in CNS (central nervous system) diseases in September 2023. This merger is pivotal not only for AbbVie's growth but also signifies a consolidation trend within the CNS therapeutics sector. By integrating innovative technologies and pipeline assets, AbbVie aims to bolster its competitive edge significantly in the demyelinating diseases market. This merger highlights the increasing interconnectedness of the pharmaceutical ecosystem, pivoting around collaboration to enhance therapeutic effectiveness and patient outcomes. Industry observers anticipate that this will prompt increased mergers and acquisitions in the sector as firms seek similar synergies to expedite drug development processes. Company Name: Sanofi S.A. Month & Year: October 2023 Type of Development: Product Launch Detailed Analysis: Sanofi unveiled a new monoclonal antibody therapy for treating relapsing forms of MS in October 2023, expanding its treatment arsenal significantly in this field. The introduction of this therapy reflects a commitment to advancing treatment modalities through innovative science. Furthermore, the development showcases a broader industry trend toward biologics and targeted therapies for demyelinating diseases. Market responses indicate that healthcare professionals and payers are eager for alternatives that provide safety and efficacy. This influx of new treatment options may fuel competitive pressure on existing therapies, leading to potential price adjustments and altering market dynamics. Company Name: Teva Pharmaceutical Industries Ltd. Month & Year: November 2023 Type of Development: Partnership Detailed Analysis: Teva announced a strategic partnership with a technology firm to collaborate on AI-driven approaches to MS treatment and patient management in November 2023. This partnership underscores a growing trend of incorporating technology into healthcare to enhance drug discovery and patient outcomes. By utilizing AI, Teva aims to streamline clinical research and tailor therapies to individual patient needs, thereby enhancing therapeutic efficacy. The collaboration could reshape how the pharmaceutical industry conducts research and develops therapies for demyelinating diseases, prompting competitors to explore similar integrations of advanced technologies, ultimately driving innovation in the market. This report is also available in the following languages : Japanese (脱髄疾患治療薬市場), Korean (탈수초성 질환 치료제 시장), Chinese (脱髓鞘疾病治疗市场), French (Marché des thérapies contre les maladies démyélinisantes), German (Markt für Therapeutika gegen demyelinisierende Erkrankungen), and Italian (Mercato terapeutico delle malattie demielinizzanti), etc. Request Sample Pages: More Research Finding – Human Granulocytic Ehrlichiosis Drug Market The market for drugs targeting Human Granulocytic Ehrlichiosis (HGE) is valued at approximately $320 million. Given the rising incidence of tick-borne diseases and increased awareness among healthcare professionals, the market is projected to grow significantly, reaching an estimated value of $580 million by 2034. This indicates a compound annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Lymphopenia Therapeutics Market The global lymphopenia therapeutics market is valued at approximately $3.2 billion, driven by increasing awareness of immune disorders and advancements in biologics and immunotherapies. The market is projected to grow significantly, reaching an estimated $6.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period of 2025 to 2034. Cytochrome C Antibody Market The global Cytochrome C Antibody market is valued at approximately $210 million in 2024, driven by increasing research activities in cell apoptosis and related diseases. The market is projected to reach around $350 million by 2034, reflecting a robust growth trajectory fueled by advancements in biotechnology and rising prevalence of cancer and neurodegenerative disorders. AMPK Antibody Market The AMPK antibody market is valued at approximately $1.2 billion, fueled by the growing demand for research products in metabolic diseases and cancer therapy. The market is projected to reach about $2.5 billion by 2034, reflecting accelerating advancements in biotechnology and personalized medicine. Threonine Protein Kinase Chk1 Antibody Insights 2024 The market for Threonine Protein Kinase Chk1 Antibodies is poised for significant growth, with a projected market value of approximately $250 million by 2024. Over the forecast period from 2025 to 2034, the market is expected to expand, reaching an estimated value of $500 million. This growth represents a compound annual growth rate (CAGR) of around 8.5%. TrkC Antibody Market The TrkC antibody market was valued at approximately $1.5 billion in 2024, driven by increasing research funding and rising demand for targeted cancer therapies. This niche market is expected to reach around $3.2 billion by 2034, reflecting a robust growth trajectory. The projected Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 8.2%. Androgen Antibody Market The androgen antibody market is poised for significant growth, with an estimated market value of approximately $1.2 billion in 2024. Projections indicate that this market could expand to around $2.8 billion by 2034, reflecting increasing demand for advanced diagnostic and therapeutic options in conditions related to androgen imbalance. This growth represents a Compound Annual Growth Rate (CAGR) of about 9.0% during the forecast period from 2025 to 2034. Herpesvirus Entry Mediator HVEM Protein Market The global market for the Herpesvirus Entry Mediator (HVEM) protein is valued at approximately $150 million, primarily driven by its applications in immunotherapy and viral research. The market is poised for significant growth, with a projected value of $300 million by 2034, representing a robust Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period from 2025 to 2034. Histone Deacetylase 1 HDAC1 Antibody Market The market for Histone Deacetylase 1 (HDAC1) antibodies is poised for significant growth, valued at approximately $250 million in 2024. This sector is expected to reach an estimated $750 million by 2034, driven by the rising prevalence of cancer and neurodegenerative diseases, which HDAC1 inhibitors target. The compound annual growth rate (CAGR) is projected at approximately 12% during the forecast period from 2025 to 2034. Prostaglandin-endoperoxide Synthase 2 COX-2 Antibody Market The global market for Prostaglandin-endoperoxide Synthase 2 (COX-2) antibodies is valued at approximately $1.6 billion in 2024, with a projected market value of around $3.2 billion by 2034. This growth corresponds to a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. Fecal Incontinence Therapeutics Market The fecal incontinence therapeutics market is poised for significant growth, valued at approximately $1.2 billion in 2024. By 2034, this market is projected to reach around $3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period of 2025–2034. POEMS Syndrome Treatment Market The global market for POEMS Syndrome diagnostic and therapeutic solutions is valued at approximately $700 million. The market is poised for significant growth, with projections estimating a market value of around $1.3 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.5% during the forecast period from 2025 to 2034. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market The Non-Alcoholic Steatohepatitis (NASH) therapeutics and diagnostics market was valued at approximately $4.2 billion in 2024 and is projected to reach $12 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of around 12% during the forecast period of 2025-2034. mRNA Vaccine and Therapeutics Raw Material Market The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034. Gene Editing Kit Market The gene editing kit market is projected to reach a value of approximately $5.4 billion in 2024, driven by advancements in CRISPR technology and increased applications in synthetic biology and personalized medicine. The market is expected to grow significantly, with a forecasted value of $13.2 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period from 2025 to 2034. Nanoparticles Market The global nanoparticles market is projected to reach a value of approximately $60 billion in 2024, driven by advancements in nanotechnology across various sectors, including healthcare, electronics, and energy. The market is expected to grow significantly, achieving a projected value of $120 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Bispecific T Cell Engager Therapeutics Future Trends The bispecific T cell engager (BiTE) therapeutics market is valued at approximately $7.5 billion, driven by rising incidences of hematologic malignancies and solid tumors. The market is projected to grow significantly, with an estimated value of around $20 billion by 2034. This represents a compound annual growth rate (CAGR) of about 12.3% over the forecast period from 2025 to 2034. Molecular Cancer Therapeutics Market The global molecular cancer therapeutics market is projected to reach approximately $120 billion in 2024, driven by advancements in personalized medicine and an increasing number of targeted therapies. The market is expected to grow at a robust CAGR of 8.5% from 2025 to 2034, indicating a significant demand for innovative treatments that address specific genetic and molecular profiles of tumors. Single-Cell Dispenser Market The global single-cell dispenser market is valued at approximately $580 million in 2024 and is projected to reach around $1.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio

Perimenopause or MS
Perimenopause or MS

WebMD

time2 days ago

  • WebMD

Perimenopause or MS

Get me off this ride already! The hormonal fluctuations during this perimenopause stage I'm going through are driving me nuts. This is the wildest roller coaster of my life. My MS is angry. HELP PLEASE! On previous blogs, I've mentioned that multiple sclerosis and menses are declared public enemies. And sometimes, nature is a little too generous with women. We get our first period when we're little girls. Then, it goes on and on and on for decades. If that's not enough, after we reach a certain age, we enter the infamous transition period called perimenopause. And when you have MS, it hits you like a train. I'm a hot mess! Literally. If I was miserable trying to find balance and peace between my period and multiple sclerosis, now I'm at war with my own body. I feel like I hit the wall at 100 miles per hour, but I'm still alive. I can't wait for menopause! Every time I have my period, my MS symptoms amplify, which is expected. But now, not only are they amplified to the third power, but they're constant. From the entire cycle, I think I have two good days. My hypersensitivity is to the roof. The mood swings are intense. I'm depressed for the first time in my life. Like, I've been through hell and back, and never had depression before. Sometimes, I feel like I'm acting out of character, and I'm not proud of it. But what can I do? I can't control what's happening inside of me. On top of that, the fatigue – the lack of energy – hit me like a ton of bricks. Not to mention the brain fog. Ugh! I'm hot and sweaty. Gross! The temperature intolerance is off the hook. Can anybody hear the sirens? Tornado warning! What makes the perimenopause period exhausting is that it's a gradual transition. It could last several years before you get to menopause. So, while we still have our period, which is already hard enough, we have all these different symptoms lingering around, out of control and making the calls. The irony? We're expected to ride this wave with a smile on our face. Perimenopause could worsen MS symptoms and increase the progression of the disease. Sometimes, it's hard to pinpoint whether it's MS or perimenopause. Neurodegeneration shows brain volume loss and gray matter reduction in perimenopausal women with multiple sclerosis. Sleep disruption could also contribute to cognitive decline, depression, fatigue, and memory issues. No wonder I've been so dysfunctional in all areas. I've always had problems with poor sleep, but now it's worse. I'm in need of more sleep than prior to perimenopause. I'm exhausted! Like Cher said once in an interview when she was asked: 'What do you think of getting old?' And she quickly answered: 'It sucks!' I'm there with her. 'Moving forward in time,' which I prefer to say, really takes you by surprise, and makes you look back and ask, 'Where did time go?' Various symptom management strategies are suggested, like increasing physical and brain exercises, as well as the use of medications like antidepressants or contraceptives. Mommy's little helpers to the rescue! It's so hard to be a woman. I'm starting to feel sorry for the people around me, really. I haven't been the friendliest person lately. I'm so irritable that I can't even live with myself. I mean, they're no saints either, but I definitely take things out of proportion sometimes. It's like their new hobby is to push my buttons. What's hilarious is that when I went to my gynecologist and she tested my hormonal levels, she says that I'm not even close to being in menopause and that all the levels look normal. Really? Then where is this demon inside of me coming from? She also mentioned that this phase that I'm in is like being in limbo. No joke? I could even get pregnant if I wanted to. Hilarious! So, everything looks great, everything is awesome, I'm just feeling completely decompensated and there's nothing tangible to blame. In the midst of all this, I've had to apply to my own life everything that I preach. I've been doing a lot of self-care, showing grace to myself, meditating, disconnecting, walking away, breathwork, etc. This new life challenge requires that I put a lot of work into myself and my needs. I'm trying to be patient with myself and to not be so hard on myself as well. It's hard to be me nowadays. I'm a wreck! But I will survive. There is no misfortune that lasts a hundred years nor a body that can resist it. This too shall pass. I send a hug and my best wishes to all the warriors out there reading this blog that are going through the same thing. My heart goes out to you. If you need a friend, find me on my social media or join me on our Facebook group.

Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025
Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025

Yahoo

time2 days ago

  • Yahoo

Canadian Multiple Sclerosis Nurses Among Winners of International Nightingale Award 2025

Four Canadian nurses are among eleven global recipients of the International Nightingale award for excellence in MS nursing. The awards are presented by the International Organization of Multiple Sclerosis Nurses (IOMSN) with support from Merck KGaA, Darmstadt, Germany. MISSISSAUGA, ON, June 4, 2025 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce four Canadian nurses are among the recipients of the International Organization of Multiple Sclerosis Nurses (IOMSN) 2025 International Nightingale Award. The International Nightingale Award was launched in 2020 by IOMSN, with support from Merck KGaA, Darmstadt, Germany in celebration of the International Year of the Nurse and Midwife. "As a company dedicated to advancing multiple sclerosis care for over 25 years, we recognize that MS nurses play a vital role in providing care and support to patients. We are excited to collaborate with the IOMSN in this initiative, which celebrates nursing professionals and supports impactful projects that enhance patient outcomes," said Javed Alam, Managing Director of EMD Serono Canada. Having Canadian recipients of the International Nightingale Award recognizes the significance of MS nurse contributions to patient management and highlights the leadership role that Canadian nurses play on a global level. Shantha George, a community MS nurse practitioner in Edmonton, will receive $5,000 USD to support her Fight Back: Living Well with MS Program, an initiative that focuses on lifestyle management for mental health where patients learn tips to manage anxiety and depression including breathing techniques, drumming and yoga. Stephanie McLeod, a nurse practitioner at the Alberta Neurologic Centre in Calgary will receive $5,000 USD to support the development of a new program to enhance patient and family education, empowering those affected with MS with the knowledge and support they need. Lou-Anne Robertson, a registered nurse at the Central Alberta Multiple Sclerosis Clinic in Red Deer will receive $5,000 USD to support her efforts to raise awareness about the benefits of MS nurse certification for patient care and professional growth. Trudy Campbell, a nurse practitioner at the Halifax MS Clinic, Nova Scotia Health will receive $5,000 USD to support her work on evidence informed, holistic care pathways related to health promotion to support healthy aging for persons with MS. "Since 2020, IOMSN, EMD Serono and Merck KGaA Darmstadt, Germany have proudly celebrated 'The Lady with the Lamp', Florence Nightingale, who is a symbol of compassion, data-driven care, and nursing excellence. The IOMSN Nightingale Awards empower nurses to bring bold ideas to life, driving meaningful change for those living with MS" said Bonnie Blain, President of the IOMSN. " These awards not only recognize achievement but also inspire continued innovation and leadership in nursing. We are thrilled to partner again with Merck KGaA Darmstadt, Germany to present the 2025 International Nightingale Awards. I am honored to celebrate these Canadian Nightingale Recipients whose impactful work has the potential to improve the lives of their patients and resonate across their communities." The International Nightingale Award was awarded to eleven eligible candidates who live and work in countries outside of the United States. Each will receive funding of up to 5000 US Dollars for current projects that require ongoing and/or additional funding for the growth of the program; proposed time-limited projects; personal activities that will support the professional growth and development of an MS nursing professional; and/or nursing research in MS or a related field. About Multiple SclerosisMultiple Sclerosis (MS) is a degenerative autoimmune disease in which the myelin sheath around the nerves in the brain and spinal cord are inflamed and often damaged. It is estimated that approximately 2.3 million people have MS worldwide. Canada has one of the highest rates of MS in the world with one in 385 people living with the disease. While symptoms vary, the most common symptoms of MS include extreme fatigue, lack of coordination, weakness, tingling, impaired sensation, vision problems, bladder problems, cognitive impairment and mood changes. The relapsing forms of MS are the most common type at the time of diagnosis. About the International Organization of Multiple Sclerosis Nurses (IOMSN)Founded on May 30, 1997, International Organization of Multiple Sclerosis Nurses (IOMSN) is the first and only international organization focusing solely on the needs and goals of professional nurses, anywhere in the world, who care for people with multiple sclerosis. Mentoring, educating, networking, sharing - the IOMSN supports nurses in their continuing effort to offer hope. The mission of the IOMSN is the establishment and perpetuation of a specialized branch of nursing in multiple sclerosis; to establish standards of nursing care in multiple sclerosis; to support multiple sclerosis nursing research; and to educate the health care community about multiple sclerosis; and to disseminate this knowledge throughout the world. The ultimate goal of the IOMSN is to improve the lives of all those persons affected by multiple sclerosis through the provision of appropriate healthcare services and to make hope happen! About EMD Serono, CanadaEMD Serono, Canada, is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany. EMD Serono, Canada has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono, Canada has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono, Canada has more than 100 employees across Canada with headquarters in Mississauga, Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. SOURCE EMD Serono Canada View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store